Singapore markets open in 39 minutes

Esperion Therapeutics, Inc. (ESPR)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
2.0900+0.1800 (+9.42%)
At close: 04:00PM EDT
2.1300 +0.04 (+1.91%)
After hours: 07:07PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.9100
Open1.9300
Bid2.0700 x 11300
Ask2.1000 x 3800
Day's range1.9297 - 2.1250
52-week range0.7000 - 3.4000
Volume4,928,175
Avg. volume6,274,148
Market cap395.848M
Beta (5Y monthly)0.82
PE ratio (TTM)N/A
EPS (TTM)-2.0300
Earnings date07 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est7.41
  • GlobeNewswire

    Esperion to Report First Quarter 2024 Financial Results on May 7

    ANN ARBOR, Mich., April 23, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report first quarter 2024 financial results before the market opens on Tuesday, May 7, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. Please click here to pre-register to participate in the conference call and obtain your dial in number and PIN. A live audio webcast can be accessed on the investor and me

  • Insider Monkey

    11 Best Low Price Pharma Stocks To Invest In

    In this piece, we will take a look at the 13 best low price pharma stocks to invest in. If you want to skip our overview of the pharma industry and want to skip to the five top low price stocks in this list, then you can skip ahead to 5 Best Low Price Pharma […]

  • GlobeNewswire

    Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity

    – Patients With Obesity Who Took NEXLETOL Were 23% Less Likely to Experience a Major Adverse Cardiovascular Event (MACE-4) Compared to Placebo – – NEXLETOL Demonstrated Clinical Benefit in Historically Underrepresented Groups: Women and Hispanic/Latinx Patients With and Without Cardiovascular Disease (CVD) – – CLEAR Outcomes Sets New Standards for Diversity and Inclusion with Enrollment of 48% Women and 17% Hispanic/Latinx Patients – ANN ARBOR, Mich., April 07, 2024 (GLOBE NEWSWIRE) -- Esperion